Going into partnership as a research company of interest has...

Going into partnership as a research company of interest has usually negative share price consequences prior to
the actual deal, often resulting in a 60 to 70 % price reduction, which lets the cashed up larger partner enter from a position of strength. The biotech field is littered with examples, the bigger the partner the more violent the share
price destruction and control prior to the deal.
Going by this, the last 16 months have shown stringent controls by brokers with active price suppression
and ample accumulation.


In my personal view, the 25% share issuance capacity has been arranged by company to accommodate
potential partners who often demand equity as part of the deal.

In regards to our IP patents listing frenzy this year, one could argue that we have been getting everything lined up
for partnership since initial presentations in the US in second part of last year.

IND submission and completed tox data could be the trigger moment for when both partners are ready to move
forward, do not expect any price action until then.
I view the Lions% percentage to fall below 5% and pulled forward rodent tox data as additional pieces in the
puzzle to prepare for partnership. Kidney, glaucoma and additional CNS programs could provide the ideal
deal platform needed to commit. Those programs are ongoing since last year and not shared
with the public for possibly exacting those reasons.


I, personally, got suspicious of a looming partnership ever since our US based CEO resigned, as partner company
would provide that position.
The subsequent price destruction paired with 200 mil accumulation efforts are just telling signs pointing in the
same direction.

Early 23 should see things unfold, as I see it.

all IMO